急性早期前体T淋巴细胞白血病免疫表型分析

林娜; 刘正华; 富威; 王萍萍; 颜晓菁; 李艳

doi:10.13201/j.issn.1004-2806.2019.03.009

急性早期前体T淋巴细胞白血病免疫表型分析

- 中国医科大学附属第一医院血液科(沈阳, 110001)
基金项目:
国家自然科学基金(No:81170519)

辽宁省自然科学基金(No:2013225079)

详细信息

通讯作者: 李艳,E-mail:Liyan2@medmail.com.cn

中图分类号: R733

收稿日期: 2018-12-31

Immunophenotypic analysis of early T-cell precursor lymphoblastic leukemia

- Department of Hematology, the First Affiliated Hospital of China Medical University, Shenyang, 110001, China

More Information

Corresponding author: LI Yan, E-mail: Liyan2@medmail.com.cn

Received Date: 31 December 2018

摘要

摘要: 目的:分析CD1a^-/CD8^-、My/S⁺及CD5^weak对早期前体T淋巴母细胞白血病(ETP-ALL)诊断的意义及与临床特点的关系,以提高对ETP-ALL免疫表型及临床特点的认识。方法:回顾性分析55例初诊急性T淋巴细胞性白血病患者的流式免疫分型结果,分析CD1a^-/CD8^-、My/S⁺、CD5^weak及ETP与各抗原表达阳性率的关系,以及CD1a^-/CD8^-、My/S⁺和CD5^weak两两联合对ETP诊断特异性的影响,并比较ETP(CD1a^-/CD8^-、My/S⁺、CD5^weak),near ETP(CD1a^-/CD8^-、My/S⁺、CD5⁺⁺⁺)及其他(others)组的临床基本特点。结果:多数抗原表达阳性率在CD1a^-/CD8^-和not CD1a^-/CD8^-组间、My/S⁺和My/S^-组间及ETP和non ETP组间均差异有统计学意义。但在CD5^weak和CD5⁺⁺⁺组间,各抗原表达阳性率均差异无统计学意义。CD1a^-/CD8^-联合My/S⁺对ETP的诊断特异度为75.8%,CD5^weak联合CD1a^-/CD8^-或My/S⁺对ETP的诊断特异度均为90.9%。ETP,near ETP及others组年龄、白细胞计数及血小板计数均差异有统计学意义。结论:CD1a^-/CD8^-、My/S⁺对ETP-ALL的识别与诊断具有重要意义,CD5^weak在ETP-ALL的鉴别诊断中具有重要价值,需要注意将符合CD1a^-/CD8^-、My/S⁺,但CD5高表达的near ETP患者区分出来。ETP及near ETP均具有较独特的临床特点。
- 淋巴母细胞白血病/淋巴瘤 /
- 早期前体T淋巴母细胞白血病 /
- 免疫表型
Abstract: Objective:To analyze the significance of CD1a^-/CD8^-,My/S⁺ and CD5^weak in the diagnosis of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) and their relationship with clinical characteristics,so as to improve the understanding of the immunophenotype and clinical characteristics of ETP-ALL.Method:The results of immunophenotype in 55 patients with newly diagnosed acute T-lymphoblastic leukemia were retrospectively was analyzed.The relationship between CD1a^-/CD8^-,My/S⁺,CD5^weak,ETP and the positive ratio of different antigens was analyzed.The effects of CD1a^-/CD8^-,My/S⁺,and CD5^weak on the specificity of ETP diagnosis were compared.Furthermore,basic clinical characteristics of ETP (CD1a^-/CD8^-,My/S⁺,CD5^weak),near ETP (CD1a^-/CD8^-,My/S⁺,CD5⁺⁺⁺) and other groups were compared.Result:The positive rates of most antigens were significantly different between CD1a^-/CD8^- vs not CD1a^-/CD8^- group;My/S⁺ vs My/S^- group and ETP vs non-ETP group.However,there was no significant difference of the positive rate of each antigen between CD5^weak and CD5⁺⁺⁺ group.The diagnostic specificity of CD1a^-/CD8^- combined with My/S⁺ for ETP was 75.8%,and that of CD5^weak combined with CD1a^-/CD8^- or My/S⁺ for ETP was 90.9%.There were significant differences in age,leukocyte count and platelet count among ETP,near ETP and other group.Conclusion:CD1a^-/CD8^- and My/S⁺ have great significance in the identification and diagnosis of ETP-ALL.CD5^weak has great value in the differential diagnosis of ETP-ALL.It is necessary to distinguish near ETP patients with CD1a^-/CD8^-,My/S⁺ and elevated CD5.Both ETP and near ETP have unique clinical characteristics.
- lymphoblastic leukemia/lymphoma /
- early T-cell precursor lymphoblastic leukemia /
- immunophenotype

HTML全文

参考文献(11)

[1]	Arber DA,Orazi A,Hasserjian R,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood,2016,127:2391-2405.
[2]	Inukai T,Kiyokawa N,Campana D,et al.Clinical significance of early T-cell precursor acute lymphoblastic leukaemia:results of the Tokyo Children's Cancer Study Group Study L99-15[J].Br J Haematol,2012,156:358-365.
[3]	Jain N,Lamb AV,O'Brien S,et al.Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults:a high-risk subtype[J].Blood,2016,127:1863-1869.
[4]	Zhang J,Ding L,Holmfeldt L,et al.The genetic basis of early T-cell precursor acute lymphoblastic leukaemia[J].Nature,2012,481:157-163.
[5]	Coustan-Smith E,Mullighan CG,Onciu M,et al.Early T-cell precursor leukaemia:a subtype of very high-risk acute lymphoblastic leukaemia[J].Lancet Oncol,2009,10:147-156.
[6]	Neumann M,Heesch S,Schlee C,et al.Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations[J].Blood,2013,121:4749-4752.
[7]	Neumann M,Coskun E,Fransecky L,et al.FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors[J].PLoS one,2013,8:e53190.
[8]	Wood BL,Winter SS,Dunsmore KP,et al.T-lymphoblastic leukemia (T-ALL) shows excellent outcome,lack of significance of the early thymic precursor (ETP) immunophenotype,and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children's Oncology Group (COG) Study AALL0434[J].Blood,2014,124:1-1.
[9]	Dong B,Somani AK,Love PE,et al.CD5-mediated inhibition of TCR signaling proceeds normally in the absence of SHP-1[J].Int J Mol Med,2016,38:45-56.
[10]	Mier-Aguilar CA,Cashman KS,Raman C,et al.CD5-CK2 signaling modulates erk activation and thymocyte survival[J].PLoS one,2016,11:e0168155.
[11]	Rai AK,Singh A,Saxena A,et al.Exonal switch down-regulates the expression of CD5 on blasts of acute T cell leukaemia[J].Clin Exp Immunol,2017,190:340-350.